• Mylan lands biosimilar sucker punch to Amgen’s blockbuster pharmafile
    June 07, 2018
    Mylan and Biocon have received FDA approval for their biosimilar to Amgen’s Neulasta (pegfilgrastim), setting the companies on track to snatch a chunk of the treatment’s $4.2 billion per year in sales, as recorded last year.
PharmaSources Customer Service